对于侵袭性Scedosporium/Lomentospora prolificans感染的短期和长期医疗费用知之甚少，特别是在没有血液恶性肿瘤的患者群体中。这项研究调查了超额指数住院费用和这些感染的累积费用。确定了超额费用和指数住院住院时间 (LOS) 的预测因素。这些估计为新型抗真菌药物的成本效益模型提供了宝贵的输入。在澳大利亚六家医院进行了一项回顾性病例对照研究。已证实/可能的侵入性 Scedosporium/L 病例。根据预先定义的标准，将 2011 年至 2021 年期间的增殖菌感染 (n = 34) 与对照 (n = 66) 进行匹配。成本数据是从基于活动的成本核算系统中检索的，并从澳大利亚公立医院的角度进行分析。所有费用均以 2022 年澳元 (AUD) 表示。使用中值回归分析来调整指数住院的超额费用，而使用间隔划分的生存概率来估计长达 1.5 年随访的累积费用。侵入性 Scedosporium/L。产菌感染与住院期间调整后的中位超额费用 36 422 澳元 (P = 0.003) 和 16.27  天 (P < 0.001) 的 LOS 独立相关。住院费用是主要成本驱动因素（42.7%），其次是药房费用，其中抗真菌药物占总费用的23.8%。异体造血干细胞移植增加了超额费用（P = 0.013）并延长了LOS（P < 0.001），而≤28天内的住院患者死亡则降低了费用（P = 0.001）和LOS（P < 0.001）。 Scedosporium/L 病例的中位累积费用在 1.5 年内大幅增加至 203 澳元/L。繁殖菌感染。与侵入性 Scedosporium/L 相关的经济负担。增殖菌感染是巨大的。© 作者 2023。由牛津大学出版社代表英国抗菌化疗协会出版。版权所有。如需权限，请发送电子邮件至：journals.permissions@oup.com。

Little is known about the short- and long-term healthcare costs of invasive Scedosporium/Lomentospora prolificans infections, particularly in patient groups without haematological malignancy. This study investigated excess index hospitalization costs and cumulative costs of these infections. The predictors of excess cost and length of stay (LOS) of index hospitalization were determined. These estimates serve as valuable inputs for cost-effectiveness models of novel antifungal agents.A retrospective case-control study was conducted at six Australian hospitals. Cases of proven/probable invasive Scedosporium/L. prolificans infections between 2011 and 2021 (n = 34) were matched with controls (n = 66) by predefined criteria. Cost data were retrieved from activity-based costing systems and analysis was performed from the Australian public hospital perspective. All costs were presented in 2022 Australian dollars (AUD). Median regression analysis was used to adjust excess costs of index hospitalization whereas cumulative costs up to 1.5 years follow-up were estimated using interval-partitioned survival probabilities.Invasive Scedosporium/L. prolificans infections were independently associated with an adjusted median excess cost of AUD36 422 (P = 0.003) and LOS of 16.27 days (P < 0.001) during index hospitalization. Inpatient stay was the major cost driver (42.7%), followed by pharmacy cost, of which antifungal agents comprised 23.8% of the total cost. Allogeneic haematopoietic stem cell transplant increased the excess cost (P = 0.013) and prolonged LOS (P < 0.001) whereas inpatient death within ≤28 days reduced both cost (P = 0.001) and LOS (P < 0.001). The median cumulative cost increased substantially to AUD203 292 over 1.5 years in cases with Scedosporium/L. prolificans infections.The economic burden associated with invasive Scedosporium/L. prolificans infections is substantial.© The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.